Description

Simple

A medication used to treat severe nearsightedness, a fungal infection in the eye, and the growth of new blood vessels in the eye.

Clinical

A benzoporphyrin derivative used to treat pathological myopia, ocular histoplasmosis, and choroidal neovascularization in macular degeneration.

Overview

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Pharmacology

Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Pharmacodynamic

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and,... Read more

Mechanism of action

Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothe... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.

Route of elimination

Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.

Toxicity

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to b... Read more

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Injection Site Reactions US
  • Kind: experimental
    • Percent: 10-30%
  • Varying Reports
    Visual disturbances US
  • Kind: experimental
    • Percent: 10-30%
  • Varying Reports
    Pneumonia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Cough US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Pharyngitis US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Vertigo US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Sleep Disorder US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Prostatic disorder US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Lacrimation disorder US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Decreased hearing US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Diplopia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Cataracts US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Elevated liver function tests US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    White blood cell count increased US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    White blood cell count decreased US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Anemia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Nausea US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Hypesthesia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Myasthenia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Arthrosis US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Arthralgia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Increased creatinine US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Albuminuria US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Fever US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Flu syndrome US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Infusion related pain US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Photosensitivity reactions US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Atrial Fibrillation US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Hypertension US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Peripheral vascular disorder US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Varicose Veins US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Eczema US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Constipation US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Gastrointestinal Cancers US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Blepharitis US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Cataracts US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Conjunctivitis/conjunctival injection US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Ocular Itching US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Dry Eyes US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Severe vision decrease US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Asthenia US
  • Kind: experimental
    • Percent: 1-10%
  • Varying Reports
    Musculoskeletal pain during infusion US
  • Kind: experimental
    • Percent: <1%
  • Varying Reports
    Choroidal vessel nonperfusion US
  • Kind: experimental
    • Percent: <1%
  • Varying Reports
    Retinal vessel nonperfusion US
  • Kind: experimental
    • Percent: <1%
  • Varying Reports
    Retinal Detachment US
  • Kind: experimental
    • Percent: <1%
  • Varying Reports
    Chest Pain US
  • Kind: experimental
    • Percent: <1%
  • Varying Reports

    Contraindications

    • Route:
      • Intravenous
    • Regions: US
    • Patient Conditions:
        • Name: Porphyria
        • Drugbank Id: DBCOND0008396

    Food Interactions

    Information currently not available.